Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Entero Therapeutics (ENTO)
NASDAQ:ENTO
RESEARCH TOOLSreports
Holding ENTO?
Track your performance easily
ENTO Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$0.19 - $14.51
Previous Close$0.4
Volume27.53K
Average Volume (3M)410.09K
Market Cap
$1.94M
Enterprise Value$1.73M
Total Cash (Recent Filing)$366.79K
Total Debt (Recent Filing)$159.67K
Price to Earnings (P/E)―
Beta1.67
Next Earnings
Aug 13, 2019EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-6.73
Shares Outstanding4,754,030
10 Day Avg. Volume303,240
30 Day Avg. Volume410,091
Standard Deviation0.29
R-Squared0.05
Alpha-0.13
Financial Highlights & Ratios
Price to Book (P/B)0.23
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)-0.30
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit10.00T>
Enterprise Value/Ebitda-0.12
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
Entero Therapeutics News
PremiumCompany Announcements
Entero Therapeutics Strikes Deal for Drug Trial Compliance Tech
PremiumCompany Announcements
Entero Therapeutics Welcomes Timothy Ramdeen to Board
PremiumCompany Announcements
Entero Therapeutics Grapples with Financial Strain and Compliance Issues
PremiumCompany Announcements
Entero Therapeutics Issues Shareholder Update LetterOwnership Overview
3.69% Insiders
0.43% Mutual Funds
0.68% Other Institutional Investors
95.11% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
ENTO FAQ
What was Entero Therapeutics’s price range in the past 12 months?
Entero Therapeutics lowest stock price was $0.18 and its highest was $14.51 in the past 12 months.
What is Entero Therapeutics’s market cap?
Currently, no data Available
When is Entero Therapeutics’s upcoming earnings report date?
Entero Therapeutics’s upcoming earnings report date is Aug 13, 2019 which is 1928 days ago.
How were Entero Therapeutics’s earnings last quarter?
Currently, no data Available
Is Entero Therapeutics overvalued?
According to Wall Street analysts Entero Therapeutics’s price is currently Overvalued.
Does Entero Therapeutics pay dividends?
Entero Therapeutics does not currently pay dividends.
What is Entero Therapeutics’s EPS estimate?
Entero Therapeutics’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Entero Therapeutics have?
Entero Therapeutics has 4,754,030 shares outstanding.
What happened to Entero Therapeutics’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Entero Therapeutics?
Currently, no hedge funds are holding shares in ENTO
---
Entero Therapeutics Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Blogger Sentiment
Bullish
ENTO Sentiment 100%
Sector Average 72%
Sector Average 72%
Insider Transactions
Sold Shares
Worth $209.4 over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 2.0%
Last 30 Days ▼ 2.6%
Last 30 Days ▼ 2.6%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-92.50%
12-Months-Change
Fundamentals
Return on Equity
-22.13%
Trailing 12-Months
Asset Growth
1347.89%
Trailing 12-Months
Company Description
Entero Therapeutics
AzurRx BioPharma, Inc. engages in the research and development of non-systemic biologics for the treatment of patients with gastrointestinal disorders. It focuses on MS1819-SD, and B-Lactamase program products. The company was founded on January 30, 2014 and is headquartered in Brooklyn, NY.
---
ENTO Stock 12 Month Forecast
Average Price Target
―Technical Analysis
AN2 Therapeutics, Inc.
―
Bioxcel Therapeutics
―
Verona Pharma
―
Alaunos Therapeutics
―
Best Analysts Covering ENTO
1 Year
1 Year Success Rate
1/8 ratings generated profit
1 Year Average Return
-69.92%
assigned a buy rating 6 months ago
Copying Jonathan Aschoff's trades and holding each position for 1 Year would result in 12.50% of your transactions generating a profit, with an average return of -69.92% per trade.
---